PMID: 1731011Jan 1, 1992Paper

Intravenously administered labetalol for treatment of hypertension in children

The Journal of Pediatrics
T E BunchmanE G Wood


Thirteen children (ages 9.2 +/- 3.7 years, mean +/- SD) received intravenous doses of labetalol, an alpha 1- and beta-adrenergic blocker, on 15 separate occasions for treatment of hypertension. In 12 of 15 episodes an initial dose of 0.55 +/- 0.34 mg/kg was given; in all 15 a continuous infusion of 0.78 +/- 0.39 mg/kg per hour was utilized for 67.3 +/- 57.1 hours. A significant decrease in systemic blood pressure occurred in all episodes (143/99.1 +/- 17.7/11.1 vs 115.6/72.4 +/- 7.7/9.5; p less than 0.01). A clinically unimportant yet statistically significant decrease in heart rate occurred during labetalol infusion (116.3 +/- 19.8 vs 107.8 +/- 11 beats/min; p less than 0.01). The episodes in children with creatinine clearances greater than 50 (n = 6) were compared with those with creatine clearances less than 20 ml/min per 1.73 m2 (n = 9); similar doses of labetalol were required for control of blood pressure. We conclude that infusion of labetalol is effective for control of blood pressure in children with hypertension, regardless of renal function.


Oct 1, 1990·The Journal of Pediatrics·T WellsG L Kearns
Aug 1, 1990·Annals of Internal Medicine·J A ClarkL A Tanner
Sep 1, 1981·Journal of Cardiovascular Pharmacology·C BarbieriA Bertazzoni
Jun 1, 1982·British Journal of Clinical Pharmacology·C Dal PaluG P Rossi


Oct 8, 2008·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Joseph T Flynn, Kjell Tullus
Jul 21, 2011·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Jayanthi Chandar, Gastón Zilleruelo
Mar 12, 2011·International Journal of Clinical Pharmacy·D G HornG Hempel
Jul 3, 2002·Current Treatment Options in Cardiovascular Medicine·Craig W Belsha
Mar 11, 2000·Pharmacotherapy·M E Temple, Milap C Nahata
Mar 22, 2005·Paediatric Drugs·Renee F RobinsonJohn D Mahan
Jan 29, 2011·Indian Journal of Pediatrics·Pankaj Hari, Aditi Sinha
Jan 15, 2008·Annals of Emergency Medicine·Craig W Belsha
Dec 12, 2000·Journal of Pediatric Health Care : Official Publication of National Association of Pediatric Nurse Associates & Practitioners·I Porto
Nov 28, 2013·Pharmaceuticals·Joseph D TobiasSergio D Bergese
Jan 19, 2011·Journal of Cardiovascular Pharmacology·Joseph T Flynn
Apr 1, 2005·Current Opinion in Pediatrics·Hiren P Patel, Mark Mitsnefes
May 25, 2010·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Christopher A ThomasDaniel I Feig
Sep 6, 2011·Paediatric Drugs·Christopher A Thomas
Sep 2, 2018·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Abanti Chaudhuri, Scott M Sutherland
Sep 12, 2020·Pediatric Cardiology·Joseph D TobiasCatherine D Krawczeski
Apr 25, 2021·Indian Journal of Pediatrics·Sheetal LadSuresh Kumar Angurana

Related Concepts

Pulse Rate
Hypertensive Disease
Intravenous Infusion Procedures

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Spatio-Temporal Regulation of DNA Repair

DNA repair is a complex process regulated by several different classes of enzymes, including ligases, endonucleases, and polymerases. This feed focuses on the spatial and temporal regulation that accompanies DNA damage signaling and repair enzymes and processes.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Torsion Dystonia

Torsion dystonia is a movement disorder characterized by loss of control of voluntary movements appearing as sustained muscle contractions and/or abnormal postures. Here is the latest research.

Archaeal RNA Polymerase

Archaeal RNA polymerases are most similar to eukaryotic RNA polymerase II but require the support of only two archaeal general transcription factors, TBP (TATA-box binding protein) and TFB (archaeal homologue of the eukaryotic general transcription factor TFIIB) to initiate basal transcription. Here is the latest research on archaeal RNA polymerases.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Related Papers

Pediatric Nephrology : Journal of the International Pediatric Nephrology Association
J MichaelJoseph D Tobias
Archives of Disease in Childhood
J E DealM Dillon
European Journal of Pediatrics
J M TreluyerM Cloup
© 2021 Meta ULC. All rights reserved